Made With Uberflip Content Marketing

Cell and Gene Therapies

Gene therapy and Cell therapy are overlapping fields of biomedical research with similar therapeutic goals to manipulate a patient's cells for the treatment of an inherited or acquired disease.

  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • Join us at the Inaugural Cell & Gene Exchange this May 2017

    Learn More
  • The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials underway globally. With that growth it is time for the industry to get serious about...

    Read
  • The renaissance of gene therapy

    The renaissance of gene therapy

    Gene therapy and gene editing are at the beginning of a renaissance, according to speakers at Biotech Showcase™ 2017. While sizeable challenges exist, they are being overcome, leaving the field...

    Read
  • BIO-Europe® 2016: Immunotherapies: Partnership models driving cures1:04:18

    BIO-Europe® 2016: Immunotherapies: Partnership models driving cures

    While we have seen new immunotherapies enter the market and there are many exciting products in development; we have also seen recent setbacks. The field is risky and partnerships among biotechs, phar

    Watch Video
  • BioPharm America™ 2016: Novel approach to CAR T cell therapy at UPenn Center for Cellular Immunotherapies5:54

    BioPharm America™ 2016: Novel approach to CAR T cell therapy at UPenn Center for Cellular Immunotherapies

    Avery Posey, Instructor at the Center for Cellular Immunotherapies at the University of Pennsylvania is interviewed by Samuel Murphy, Managing Partner at BioPharma Capital, Inc., about his work in CAR

    Watch Video
  • A look into Intellia’s strategy for “fixing the broken gene”

    A look into Intellia’s strategy for “fixing the broken gene”

    The field of genome editing is hot and growing. Despite legal battles over key patents on the CRISPR technology, the important work of genome editing goes on. Even the layperson can understand the...

    Read
  • BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?9:27

    BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?

    Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights po

    Watch Video
  • Single-use technology means big cost savings for bioprocessing industry

    Single-use technology means big cost savings for bioprocessing industry

    What does adoption of single-use technology mean for the bioprocessing industry?   The R&D and manufacturing of biologics and biosimilars is extremely expensive due to the amount of detail...

    Read
  • Realities of Rare Disease and the Role of Patient Investors

    Realities of Rare Disease and the Role of Patient Investors

    Guest post by Nicole Boice, Founder & CEO, Global Genes – Allies in Rare Disease Rare Disease represents the largest disease community on the planet!  With over 7,000 identified diseases,...

    Read
  • BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem12:46

    BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem

    AstraZeneca’s BioVentureHub CEO Magnus Björsne tells Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the exchange's intention to generate a climate of

    Watch Video
  • Promise of genome and cell therapies move closer to reality

    Promise of genome and cell therapies move closer to reality

    Stem cell technologies and adoptive immunotherapies are big buzzwords in the cell therapies world, with the promise of personalized therapies driving interest. Boston is a hotbed for cell and gene...

    Read
  • BIO-Europe Spring® 2016:  Accellta CEO says israeli stem cell specialist seeks global partners4:12

    BIO-Europe Spring® 2016: Accellta CEO says israeli stem cell specialist seeks global partners

    Accellta CEO Itzchak Angel speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden about the Israeli stem cell specialist's ste

    Watch Video
  • BIO-Europe Spring® 2016: AngioDesign tailoring next-generation ACE inhibitors5:07

    BIO-Europe Spring® 2016: AngioDesign tailoring next-generation ACE inhibitors

    Mario Ehlers, the chairman and founder of Angio-Design (UK) speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden about the d

    Watch Video
  • BIO-Europe Spring® 2016: 4SC AG's CSO outlines epigenetics strategy5:14

    BIO-Europe Spring® 2016: 4SC AG's CSO outlines epigenetics strategy

    4SC AG Chief Science Officer Daniel Vitt speaks to Informa senior editor and writer Sten Stovall during the BIO-Europe Spring® partnering conference in Stockholm, Sweden, outlining how the German canc

    Watch Video
  • BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?9:27

    BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?

    Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights po

    Watch Video
  • BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars7:07

    BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars

    Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, ab

    Watch Video
  • BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business5:18

    BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business

    Frank Ubags, CEO of CEVEC—a company offering industrial scale production of viral vectors for gene therapy firms—speaks with Scrip's Lucie Ellis about the types of deals the platform technology compan

    Watch Video
  • BIO-Europe Spring® 2016: TxCell plans U.S. studies in Crohn's after addressing manufacturing issues4:12

    BIO-Europe Spring® 2016: TxCell plans U.S. studies in Crohn's after addressing manufacturing issues

    TxCell SA CEO Stéphane Boissel tells Pharma Intelligence Senior Editor Sten Stovall why the French cell therapy company is exploring the therapeutic potential of regulatory T-cells (Tregs) in large-sc

    Watch Video
  • BIO-Europe Spring® 2016: Lucentis biosimilar to be sold to emerging markets by Xbrane Biopharma4:59

    BIO-Europe Spring® 2016: Lucentis biosimilar to be sold to emerging markets by Xbrane Biopharma

    The CEO of Stockholm-based Xbrane Biopharma Martin Åmark tells Pharma Intelligence Senior Editor Sten Stovall that the complex generics specialist aims to be the first to sell a biosimilar version of

    Watch Video
  • Biotech Showcase™ 2016: Interview: Placental stem therapy offers "off the shelf" promise9:51

    Biotech Showcase™ 2016: Interview: Placental stem therapy offers "off the shelf" promise

    Pluristem Therapeutics chairman and CEO Zami Aberman explains to Mike Ward, global director of content for Informa Pharma Insights how stem cell therapy will shape the industry. Using placental cells

    Watch Video
  • loading
    Loading More...